CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer by Seini Moimoi | Dec 5, 2023 | Portfolio News
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer by Seini Moimoi | Nov 30, 2023 | Portfolio News
Nalu Medical, Inc., Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journal by Seini Moimoi | Nov 29, 2023 | Portfolio News
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023 by Seini Moimoi | Nov 14, 2023 | Portfolio News
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders by Seini Moimoi | Nov 7, 2023 | Portfolio News
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 by Seini Moimoi | Nov 4, 2023 | Portfolio News